As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its ...

To compile our list of the best short squeeze stocks, we made use of stocks screeners to note down stocks with significant ...

Fintel reports that on November 26, 2025, Chardan Capital maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

Cathie Wood, CEO of Ark Investment Management, typically focuses on small- and mid-cap technology stocks. But she occasionally ventures into megacap growth stocks. This strategy, which likely aims to ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

Mount Sinai and Israel’s largest medical center are using artificial intelligence to map the hidden corners of the human ...

Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

USA News Group News Commentary ? The autologous cell therapy market surpassed $10.1 billion in 2025 as biotechnology companies race to commercialize therapies that read, replace, and rewrite cellular ...

Semiconductor industry giant Applied Materials Inc. beat expectations for its latest financial results and forecast higher sales in the coming year thanks to artificial intelligence demand, but its ...

Fintel reports that on November 12, 2025, Citigroup maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Buy recommendation. Analyst Price Forecast Suggests 57.77% Upside As of November 8 ...